INTELLIGENT BIO SOLUTIONS INC. 8K

Intelligent Bio Solutions Inc. announced strong fiscal 2026 revenue and margin growth, expanding customer adoption and advancing toward an FDA 510(k) submission to support entry into the U.S. drug screening market.

On August 19, 2026, Intelligent Bio Solutions Inc. reported its financial results for the fiscal year ended June 30, 2026, highlighting 38% year-over-year revenue growth to $4.2 million, a 64% increase in gross profit with gross margin expanding 778 basis points to 48.63%, and operational momentum driven by a 22% increase in its reader installed base and 35% growth in high-margin consumable cartridges, alongside progress toward FDA 510(k) clearance and planned U.S. market entry for its Intelligent Fingerprinting Drug Screening System. The company emphasized structural improvements in its cost base, including a strategic manufacturing transition to Syrma Johari, expansion to 502 active customers across safety-critical industries, and completion of key clinical, technical, and usability studies underpinning its anticipated second-half 2026 FDA submission, while continuing to operate at a net loss as it invests in commercialization and regulatory activities.

Filing Facts

CIK

1725430

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-039140

Alert Tier

6